[144] Surgery Partners, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 summary for Surgery Partners, Inc. (SGRY)

This Form 144 notifies a proposed sale of 47,491 shares of common stock via UBS Financial Services Inc. on 08/08/2025 on NASDAQ. The filing reports an aggregate market value of $1,110,769 and lists total shares outstanding as 128,209,410. All listed shares were acquired via equity vesting from Surgery Partners on dated entries between 08/28/2022 and 03/02/2025. The table of vesting entries sums to the 47,491 shares to be sold. The filing indicates no securities sold in the past three months ("Nothing to Report").

Insights

Securities Analyst

TL;DR: Routine insider sale notice; quantity and value disclosed, no recent prior sales reported.

The Form 144 is a standard compliance disclosure identifying an intended sale of 47,491 SGRY shares with an aggregate market value of $1,110,769 through UBS on 08/08/2025. The filing shows these shares were acquired entirely through equity vesting across multiple dates from 2022 to 2025, and the vesting entries listed total the shares to be sold. There are no reported securities sold in the past three months. From a trading-impact standpoint, the filing documents intent to sell but does not itself indicate market-moving information beyond the disclosed size and timing.

Corporate Governance Expert

TL;DR: Disclosure meets Rule 144 notice requirements; reflects insider monetization of vested equity.

The notice complies with Rule 144 formalities by specifying broker, planned sale date, share count, aggregate value, and acquisition history. All shares flagged were received via equity compensation/vesting, and the filing explicitly states no other sales in the prior three months. This is a routine governance event documenting an insider sale plan rather than a corporate operational or governance change.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	47491	1110769	128209410	08/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/28/2022	Equity Vesting	Surgery Partners, Inc.			259	08/28/2022	Equity Compensation
Common	02/01/2023	Equity Vesting	Surgery Partners, Inc.			2517	02/01/2023	Equity Compensation
Common	02/10/2023	Equity Vesting	Surgery Partners, Inc.			1288	02/10/2023	Equity Compensation
Common	02/24/2023	Equity Vesting	Surgery Partners, Inc.			4227	02/24/2023	Equity Compensation
Common	03/10/2023	Equity Vesting	Surgery Partners, Inc.			805	03/10/2023	Equity Compensation
common	03/13/2023	Equity Vesting	Surgery Partners, Inc.			3831	03/13/2023	Equity Compensation
common	02/01/2024	Equity Vesting	Surgery Partners, Inc.			1367	02/01/2024	Equity Compensation
Common	02/10/2024	Equity Vesting	Surgery Partners, Inc.			2230	02/10/2024	Equity Compensation
common	03/02/2024	Equity Vesting	Surgery Partners, Inc.			3674	03/02/2024	Equity Compensation
common	03/10/2024	Equity Vesting	Surgery Partners, Inc.			766	03/10/2024	Equity Compensation
common	01/31/2025	Equity Vesting	Surgery Partners, Inc.			15092	01/31/2025	Equity Compensation
common	02/01/2025	Equity Vesting	Surgery Partners, Inc.			2515	02/01/2025	Equity Compensation
common	02/28/2025	Equity Vesting	Surgery Partners, Inc.			4873	02/28/2025	Equity Compensation
common	03/02/2025	Equity Vesting	Surgery Partners, Inc.			4047	03/02/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the SGRY Form 144 disclose?

The filing discloses a proposed sale of 47,491 common shares of Surgery Partners via UBS Financial Services on 08/08/2025 with aggregate market value $1,110,769.

How were the shares acquired that are being sold?

All listed shares were acquired through equity vesting from Surgery Partners on dates between 08/28/2022 and 03/02/2025 as shown in the filing.

Does the filing report any recent sales of SGRY shares by the same person?

The Form 144 states "Nothing to Report" for securities sold during the past three months.

What broker is handling the proposed sale?

The broker listed is UBS Financial Services Inc., 1000 Harbor Blvd, 3rd Floor, Weehawken, NJ 07086.

What is the total number of SGRY shares outstanding reported in the filing?

The filing reports 128,209,410 shares outstanding.